| 2025-12-08 |
Assembly Biosciences |
Results Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes assemblybio.com ↗
76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 |
| 2025-10-10 |
Assembly Biosciences |
Results Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe assemblybio.com ↗
Statistically significant reductions in HSV-2 shedding rate, high viral load shedding rate and genital lesion rate observed in the cohort evaluating 350 mg weekly oral dose compared to placebo |
| 2025-08-08 |
Assembly Biosciences |
Results Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes assemblybio.com ↗
|
| 2025-07-26 |
Assembly Biosciences |
Results Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop assemblybio.com ↗
|
| 2025-04-09 |
Assembly Biosciences |
Results Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress assemblybio.com ↗
Preclinical data also reinforce a PK profile supportive of the potential for once-weekly or once-monthly oral dosing and demonstrate distribution of ABI-5366 to tissues relevant to HSV infection. |
| 2024-09-23 |
Assembly Biosciences |
Results Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 assemblybio.com ↗
today announced positive interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study evaluating ABI-5366 |
| 2024-07-15 |
Assembly Biosciences |
Results Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop assemblybio.com ↗
|
| 2023-07-17 |
Assembly Biosciences |
Results Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop assemblybio.com ↗
In both the oral and poster presentation entitled “ Pre-clinical characterization of ABI-5366: a highly potent long-acting helicase-primase inhibitor for the treatment of high recurrence genital herpes,” data describe ABI-5366’s low-nanomolar potency in vitro against both HSV-1 and HSV-2 clinical isolates. |
| 2023-06-07 |
Assembly Biosciences |
Results Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023 assemblybio.com ↗
We are excited to present these data describing ABI-5366’s compelling preclinical profile, including low nanomolar potency in vitro against both HSV-1 and HSV-2, the potential for long-acting oral administration and non-GLP safety data to date showing that the candidate has been well tole |